2370013-12-8 ((Sunvozertinib)

舒沃替尼;

sunvozertinib;L1Q2K5JYO8;Sunvozertinib [INN];GTPL11672;Example 52 [WO2019149164A1];2-Propenamide, N-(5-((4-((5-chloro-4-fluoro-2-(1-hydroxy-1-methylethyl)phenyl)amino)-2-pyrimidinyl)amino)-2-((3R)-3-(dimethylamino)-1-pyrrolidinyl)-4-methoxyphenyl)-;N-[5-[[4-[5-chloro-4-fluoro-2-(2-hydroxypropan-2-yl)anilino]pyrimidin-2-yl]amino]-2-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-4-methoxyphenyl]prop-2-enamide;CHEMBL5314564;ASYM-122507;2370013-12-8;EX-A6612;(R)-N-(5-((4-((5-chloro-4-fluoro-2-(2-hydroxypropan-2-yl)phenyl)amino)pyrimidin-2-yl)amino)-2-(3-(dimethylamino)pyrrolidin-1-yl)-4-methoxyphenyl)acrylamide;Sunvozertinib [WHO-DD];DZ'0586;UNII-L1Q2K5JYO8;D12506;DZ00000586;DA-67862;CS-0204146;Sunvozertinib (USAN/INN);HY-132842;A-1801;BDBM536927;DZD-9008;US11896597, Compound 77;A1801;2-Propenamide, N-[5-[[4-[[5-chloro-4-fluoro-2-(1-hydroxy-1-methylethyl)phenyl]amino]-2-pyrimidinyl]amino]-2-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-4-methoxyphenyl]-;DZD 9008;EGFR/HER2 Inhibitor DZD9008;G18377;MS-30456;DZ-0586;DZD9008;SUNVOZERTINIB [USAN];N-(5-((4-(5-chloro-4-fluoro-2-(2-hydroxypropan-2-yl)anilino)pyrimidin-2-yl)amino)-2-((3R)-3-(dimethylamino)pyrrolidin-1-yl)-4-methoxyphenyl)prop-2-enamide;Example 52 (WO2019149164A1);2-Propenamide, N-[5-[[4-[[5-chloro-4-fluoro-2-(1-hydroxy-1- methylethyl)phenyl]amino]-2-pyrimidinyl]amino]-2-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-4-methoxyphenyl]-;US11896597, Compound 52;DZ0586;GLXC-25829;SCHEMBL21232131;N-{5-[(4-{[5-chloro-4-fluoro-2-(1-hydroxy-1-methylethyl)phenyl]amino}pyrimidin-2-yl)amino]-2-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-4-methoxyphenyl}prop-2-enamide;

BTMKEDDEMKKSEF-QGZVFWFLSA-N

1S/C29H35ClFN7O3/c1-7-27(39)34-22-14-23(25(41-6)15-24(22)38-11-9-17(16-38)37(4)5)35-28-32-10-8-26(36-28)33-21-13-19(30)20(31)12-18(21)29(2,3)40/h7-8,10,12-15,17,40H,1,9,11,16H2,2-6H3,(H,34,39)(H2,32,33,35,36)/t17-/m1/s1

ClC1C(=CC(=C(C=1)NC1=CC=NC(=N1)NC1C(=CC(=C(C=1)NC(C=C)=O)N1CC[C@H](C1)N(C)C)OC)C(C)(C)O)F